Sequencing Explains 'Outlier' Patient Response to Everolimus, Shows Promise for Drug Repositioning | GenomeWeb

Sequencing the genome of a cancer bladder patient who responded exceptionally well to a cancer drug that failed in most other patients in a clinical trial, researchers have identified mutations that might serve as predictors of sensitivity to the drug.

The approach – sequencing the tumor genomes of "outlier" patients – might prove useful more generally to salvage cancer drugs that only work in specific patient groups, though pinpointing the right mutations might be challenging.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.